MARKET

TBPH

TBPH

Theravance Bioph
NASDAQ
10.16
+0.14
+1.40%
Closed 16:02 09/28 EDT
OPEN
10.17
PREV CLOSE
10.02
HIGH
10.27
LOW
10.07
VOLUME
1.77M
TURNOVER
--
52 WEEK HIGH
13.17
52 WEEK LOW
7.18
MARKET CAP
776.50M
P/E (TTM)
-7.4438
1D
5D
1M
3M
1Y
5Y
Theravance to purchase $95M of ordinary shares
Theravance Biopharma, Inc. (NASDAQ:TBPH), a company fo...
Seekingalpha · 1d ago
BRIEF-Theravance Biopharma Announces Tender Offer For Up To $95 Million Of Its Ordinary Shares
BRIEF-Theravance Biopharma Announces Tender Offer For Up To $95 Million Of Its Ordinary Shares
Reuters · 1d ago
Theravance Biopharma Launches up to $95 Million Tender Offer for Ordinary Shares
Theravance Biopharma Launches up to $95 Million Tender Offer for Ordinary Shares
MT Newswires · 1d ago
Company News for Sep 20, 2022
Companies in The News Are: WIX,COIN,TBPH,GSK,MRNA
Zacks · 09/20 13:36
Here's Why Theravance Biopharma Shares Are Moving
Theravance Biopharma Inc (NASDAQ: TBPH) shares are trading higher by 2.78% to $10.35 Monday afternoon after the company authorized a $250 million capital return program. What Else?
Benzinga · 09/19 19:02
Theravance Outlines $250M Capital Return Program; To Repurchase GSK's Entire Holdings
Benzinga · 09/19 18:28
Theravance Biopharma announces $250M capital return program
Theravance Biopharma (NASDAQ:TBPH) has launched a $250M capit...
Seekingalpha · 09/19 10:26
BRIEF-Theravance Biopharma Initiates $250 Mln Capital Return Program
BRIEF-Theravance Biopharma Initiates $250 Mln Capital Return Program
Reuters · 09/19 10:13
More
About TBPH
Theravance Biopharma, Inc. is a biopharmaceutical company primarily focused on the discovery, development and commercialization of respiratory medicines. The Company develops transformational medicines to improve the lives of patients suffering from respiratory illnesses. The Company's research is engaged in the areas of inflammation and immunology. Its Nezulcitinib (TD-0903) product is a lung-selective pan Janus-associated kinase inhibitor designed for inhaled delivery, is under development for treatment of acute lung injury associated with coronavirus disease 2019. The Company is also developing lung-selective medicines to treat respiratory disease, including YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease. Its revefenacin is a long-acting muscarinic antagonist (LAMA). Its programs also include Nezulcitinib, Ampreloxetine (TD-9855), Velusetrag (TD-5108), Selective 5-HT4 Agonist (TD-8954).

Webull offers kinds of Theravance Biopharma Inc stock information, including NASDAQ:TBPH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TBPH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TBPH stock methods without spending real money on the virtual paper trading platform.